SCHEMBL4782222

SCHEMBL4782222

CCOP(=O)(NCCOCc1csc(NC(=O)NCc2ccc(Cl)c(Cl)c2)n1)OCC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.41
ALOX12 P18054 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 2/20 0.40
ROCK1 Q13464 10/20 0.39
ROCK2 O75116 9/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 2/20 0.39
AURKA O14965 1/20 0.39
DYRK3 O43781 1/20 0.39
PRKD3 O94806 1/20 0.39
PRKCG P05129 1/20 0.39
PRKACA P17612 1/20 0.39
RPS6KB1 P23443 1/20 0.39
MARK3 P27448 1/20 0.39
AKT1 P31749 1/20 0.39
CSNK1D P48730 1/20 0.39
CLK2 P49760 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4780046 0.88 TSHR (0.46) LMNAKDM4EGAAALOX12SMN1; SMN2
SCHEMBL4726401 0.86 LMNA (0.42) LMNASMN1; SMN2TSHRROCK1ROCK2
SCHEMBL4726089 0.86 TSHR (0.50) SMN1; SMN2TSHRROCK1ROCK2MAPK1
SCHEMBL4778605 0.86 ROCK1 (0.42) LMNASMN1; SMN2TSHRROCK1ROCK2
SCHEMBL4777271 0.86 ROCK1 (0.48) LMNASMN1; SMN2TSHRROCK1ROCK2
SCHEMBL4726154 0.85 ROCK1 (0.42) LMNASMN1; SMN2TSHRROCK1ROCK2
SCHEMBL4726471 0.85 ROCK1 (0.47) LMNATSHRROCK1ROCK2MAPK1
SCHEMBL4777278 0.85 ROCK1 (0.44) LMNASMN1; SMN2TSHRROCK1ROCK2
SCHEMBL4725491 0.85 ROCK1 (0.47) LMNATSHRROCK1ROCK2MAPK1
SCHEMBL4780457 0.84 ROCK1 (0.45) LMNATSHRROCK1ROCK2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716320-B2 Antibacteriall heterocyclic ureas REPLIDYNE, INC. (US) 2014-05-06 US claimed
US-20080207703-A1 Antibacterial heterocyclic ureas REPLIDYNE, INC. (US) 2008-08-28 US claimed
WO-2008011191-A1 ANTIBACTERIAL HETEROCYCLIC UREAS REPLIDYNE, INC. (US) 2008-01-24 WO claimed
US-8716320-B2 Antibacteriall heterocyclic ureas REPLIDYNE, INC. (US) 2014-05-06 US disclosed
US-20080207703-A1 Antibacterial heterocyclic ureas REPLIDYNE, INC. (US) 2008-08-28 US disclosed
WO-2008011191-A1 ANTIBACTERIAL HETEROCYCLIC UREAS REPLIDYNE, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207703-A1 Antibacterial heterocyclic ureas UMPS, UROD, UGP2 LMNA 3271/4885KDM4E 1973/4885GAA 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.